Entinostat (MS-275)

製品コードS1053 別名:SNDX-275

Entinostat (MS-275)化学構造

分子量(MW):376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

サイズ 価格(税別)  
JPY 15106.00
JPY 11620.00
JPY 24900.00
JPY 44820.00
JPY 127820.00

文献中Selleckの製品使用例(63)

カスタマーフィードバック(14)

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

  • B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
ターゲット
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
体外試験

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT3TGxHUUN3ME2wMlA3OSEQvF2= MlvOV2FPT0WU
ALL-PO NF60bHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXO3[|ZEUUN3ME2wMlA3OzV3IN88US=> MnHkV2FPT0WU
697 MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILuRW5KSzVyPUCuNFk6PzZizszN NX;oOlFRW0GQR1XS
NCI-H748 M1zKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nTeGlEPTB;MD6xNFM{PCEQvF2= MnfQV2FPT0WU
NKM-1 MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPnWW5EUUN3ME2wMlExQTF{IN88US=> NGLPXpNUSU6JRWK=
ES1 NX;UZXJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLhZ2czUUN3ME2wMlEyOjV3IN88US=> MVzTRW5ITVJ?
NCI-H1963 M1zHV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHDfJBKSzVyPUCuNVE2PzlizszN NEPUNWtUSU6JRWK=
NCI-H1417 M{nzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHwSJpKSzVyPUCuNVI6PzRizszN M3jFZXNCVkeHUh?=
NEC8 MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMUO1Nlch|ryP NEfP[HVUSU6JRWK=
CRO-AP2 Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\BTWM2OD1yLkG2PFg6KM7:TR?= NYX6SlBwW0GQR1XS
A3-KAW MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMUe2Nlch|ryP NVLZbHVFW0GQR1XS
SF539 M2H0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwMUm1PVMh|ryP MXfTRW5ITVJ?
NOS-1 NELJfYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonVTWM2OD1yLkG5OlE6KM7:TR?= MlnpV2FPT0WU
NTERA-S-cl-D1 M{XQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvKTWM2OD1yLkKwNVE{KM7:TR?= NUjrT|VxW0GQR1XS
COR-L88 M2DHRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fPTWlEPTB;MD6yNlk2QSEQvF2= MX7TRW5ITVJ?
EM-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV60[pMzUUN3ME2wMlI1ODd7IN88US=> Mn\3V2FPT0WU
KARPAS-45 M2fremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPUdolKSzVyPUCuNlc5OzNizszN MoHNV2FPT0WU
DSH1 NFjKfZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjCZ3RKSzVyPUCuNlg4ODhizszN Mkf5V2FPT0WU
HT-144 NELkdFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLYTWM2OD1yLkOwNlU3KM7:TR?= MWLTRW5ITVJ?
ATN-1 NFzrc|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjQXmpKSzVyPUCuN|A2PzZizszN NHTIR3BUSU6JRWK=
HEL NIfSTHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3K3VmlEPTB;MD6zNVM1QCEQvF2= NF;MbWtUSU6JRWK=
NB12 MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33ZOmlEPTB;MD6zNVc2PiEQvF2= NWXScnF6W0GQR1XS
LU-139 NGHG[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHKe|NKSzVyPUCuN|M2OSEQvF2= MkTuV2FPT0WU
J-RT3-T3-5 NY\Ue3pLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi5N3pWUUN3ME2wMlM{PzF4IN88US=> Mn;4V2FPT0WU
MOLT-13 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTLTWM2OD1yLkOzPFEh|ryP M3qweXNCVkeHUh?=
SR NYf1PJpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwM{SyOlEh|ryP MV\TRW5ITVJ?
CMK NEPG[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkn3TWM2OD1yLkO1O|I4KM7:TR?= MUjTRW5ITVJ?
ES8 M3XweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFH3XpNKSzVyPUCuN|YxOjJizszN NUPxTHBpW0GQR1XS
LB647-SCLC NFv2bXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjicZBEUUN3ME2wMlM3PzNizszN MoHNV2FPT0WU
TE-8 NXTzc|RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILRPYlKSzVyPUCuN|Y6OzVizszN MYrTRW5ITVJ?
BV-173 M4\3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknQTWM2OD1yLkO3NVIyKM7:TR?= M2PmZnNCVkeHUh?=
DEL M3Lodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwM{e0PFch|ryP MYrTRW5ITVJ?
ARH-77 M{\FXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfnTWM2OD1yLkO4NVk{KM7:TR?= NWfaOW1zW0GQR1XS
NCCIT M1mzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwM{i2OFkh|ryP NVq3[2loW0GQR1XS
RPMI-8402 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{npUGlEPTB;MD6zPFcxOSEQvF2= MmDOV2FPT0WU
MONO-MAC-6 M2\od2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nYeWlEPTB;MD6zPFc4PiEQvF2= NEfXRpBUSU6JRWK=
SK-MM-2 MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnuTWM2OD1yLkO5PFY5KM7:TR?= MXPTRW5ITVJ?
CHP-126 MlzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETDc4VKSzVyPUCuOFAzOzFizszN MmTFV2FPT0WU
A101D MnruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwNECzJO69VQ>? NGTXZ|BUSU6JRWK=
SCH NUmxSFF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HoRWlEPTB;MD60NFM1OiEQvF2= NVXLbXlUW0GQR1XS
NMC-G1 M4r5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfT[pNKSzVyPUCuOFA{PjdizszN MnHQV2FPT0WU
NCI-H209 MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\ib3VKSzVyPUCuOFA3OTNizszN NHe4XI9USU6JRWK=
MOLT-16 NGDGO45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDpWZI{UUN3ME2wMlQyODF5IN88US=> MmHiV2FPT0WU
RPMI-6666 Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfDTWM2OD1yLkSxNVIh|ryP M37ScHNCVkeHUh?=
OPM-2 NY\QVVI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTuTWM2OD1yLkSxOVE{KM7:TR?= M{jKV3NCVkeHUh?=
MRK-nu-1 NEfle25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLNS2dKSzVyPUCuOFMyPTNizszN MWHTRW5ITVJ?
BC-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPM[ppKSzVyPUCuOFM1ODNizszN MkW5V2FPT0WU
MHH-NB-11 M2jQUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGO3eGZKSzVyPUCuOFM1PTNizszN M33SPXNCVkeHUh?=
Ramos-2G6-4C10 NIHRUZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGSyUlVKSzVyPUCuOFM5QTdizszN NW\VN4xPW0GQR1XS
LS-513 MnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrTTWM2OD1yLkS0OVAyKM7:TR?= M2nIOHNCVkeHUh?=
K5 MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;FcmlEPTB;MD60O|AzPSEQvF2= MlziV2FPT0WU
HOP-62 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwNEizOVgh|ryP NWi4WIQ{W0GQR1XS
NCI-H187 NX\QN|I6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLLTWM2OD1yLkS5NlI4KM7:TR?= NX7xNItQW0GQR1XS
BE-13 NUHXRYljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHG1R2tKSzVyPUCuOFk3PjFizszN MYfTRW5ITVJ?
HC-1 MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkizTWM2OD1yLkWwOFc{KM7:TR?= M1TqenNCVkeHUh?=
ACN NEm2OGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PQ[2lEPTB;MD61NVAzQCEQvF2= M1Gx[nNCVkeHUh?=
HCC1599 NFe5T3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHP3NIZKSzVyPUCuOVE2PyEQvF2= NEn6S|NUSU6JRWK=
MV-4-11 M3SxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\Cb2lEPTB;MD61N|A1OSEQvF2= MnjtV2FPT0WU
LC-2-ad NFv0VIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHmTWM2OD1yLkWzOlY{KM7:TR?= M33wWnNCVkeHUh?=
HL-60 NIrCfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTWdmZUUUN3ME2wMlU1OjZzIN88US=> MmHYV2FPT0WU
NB17 NVK3Upc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlS2TWM2OD1yLkW0N|gh|ryP NEDWXHlUSU6JRWK=
TE-1 NXzabXE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoL0TWM2OD1yLkW1N|A3KM7:TR?= NH\5SHBUSU6JRWK=
NCI-H524 NHXMW2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHvVnpKSzVyPUCuOVU1ODFizszN M2rad3NCVkeHUh?=
MZ7-mel M37NeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\4eo5CUUN3ME2wMlU3OTB3IN88US=> NVz0S5h[W0GQR1XS
L-363 NFjhWVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2OyUWlEPTB;MD61OlY2PyEQvF2= MWDTRW5ITVJ?
BL-41 NWHNfIxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHOeWZKSzVyPUCuOVY5QDlizszN NHzBe5ZUSU6JRWK=
LU-134-A MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnL[2twUUN3ME2wMlU4ODd|IN88US=> MUnTRW5ITVJ?
SIG-M5 NIXJWVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TkSWlEPTB;MD61O|g1QCEQvF2= M4DoSnNCVkeHUh?=
ONS-76 M1SzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DWfWlEPTB;MD61PFI1OiEQvF2= NVXk[m5RW0GQR1XS
KARPAS-299 NUOxc3hPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwNUi1NFQh|ryP MkS0V2FPT0WU
DU-4475 MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoryTWM2OD1yLkW4O|A{KM7:TR?= NX7HXWt1W0GQR1XS
NB69 MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjnd4NkUUN3ME2wMlU6QDJ3IN88US=> NUnUdXhiW0GQR1XS
MHH-PREB-1 MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zRZmlEPTB;MD62NFcyQSEQvF2= NWHPZm5yW0GQR1XS
LU-165 NIPpVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIGzZZpKSzVyPUCuOlE5OTJizszN Mlr5V2FPT0WU
LOUCY MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvPc3pKSzVyPUCuOlM{PjRizszN Mn7JV2FPT0WU
NCI-H526 NHvLNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrLdlhbUUN3ME2wMlY{PTRzIN88US=> NV3pZmtLW0GQR1XS
KE-37 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jSfWlEPTB;MD62OFI4PiEQvF2= Mn32V2FPT0WU
NALM-6 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\JW2lEPTB;MD62OFg3KM7:TR?= NVLqdGJ{W0GQR1XS
CW-2 MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLWTWM2OD1yLk[1O|k1KM7:TR?= NGPJe25USU6JRWK=
SU-DHL-1 NYj0eXdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwNkW5OFch|ryP NEHQPVVUSU6JRWK=
NB13 MniwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEniN5pKSzVyPUCuOlY5OTdizszN M3rtO3NCVkeHUh?=
QIMR-WIL NVGwS4UzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHrSJhlUUN3ME2wMlY5OzR|IN88US=> NEfofJVUSU6JRWK=
ECC12 NGfEclRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXe5[pNRUUN3ME2wMlcxODh4IN88US=> NVH2bHpMW0GQR1XS
KALS-1 NGj2TGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnmTWM2OD1yLkewOFkzKM7:TR?= MXXTRW5ITVJ?
COR-L279 MkDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV61[pgyUUN3ME2wMlcxQTl4IN88US=> NH3QVYRUSU6JRWK=
NB14 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;5TWM2OD1yLkeyOlE4KM7:TR?= NGjY[29USU6JRWK=
CCRF-CEM MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwN{S2OlEh|ryP NIrITWdUSU6JRWK=
SW954 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjzTWM2OD1yLke1PVk6KM7:TR?= NHe5RmJUSU6JRWK=
IST-SL1 NGLXcnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2roRWlEPTB;MD63O|M1QCEQvF2= MkTaV2FPT0WU
LAMA-84 M2XYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEGzW25KSzVyPUCuO|c2PjdizszN NEHBfJNUSU6JRWK=
Daudi NETVPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlr1TWM2OD1yLke3OlgyKM7:TR?= NXXsR5c1W0GQR1XS
BC-3 NWDhPGZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwN{izNFgh|ryP NH62ZnZUSU6JRWK=
HCC2998 NFLMfGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwN{izOkDPxE1? NHflNmNUSU6JRWK=
NCI-H69 NXHJfnpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;FTFRKSzVyPUCuPFAyPDdizszN M1;IenNCVkeHUh?=
CPC-N Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTTdG45UUN3ME2wMlgxPTJ2IN88US=> NXHqU|VlW0GQR1XS
NOMO-1 Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjPPWlJUUN3ME2wMlgyODh2IN88US=> MXvTRW5ITVJ?
CESS MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwOEGxPVch|ryP MkjQV2FPT0WU
LC4-1 NX7VdXd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHDTWM2OD1yLki0NFA4KM7:TR?= NHfEfHBUSU6JRWK=
BL-70 NEnkdWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwOEW3NFIh|ryP NWXHW4N7W0GQR1XS
ES4 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTwTWM2OD1yLki1PFY5KM7:TR?= M1iwS3NCVkeHUh?=
HCE-T M1rtfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLXOHlPUUN3ME2wMlg4OTdzIN88US=> M1XJNXNCVkeHUh?=
JAR NWL3RoZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7nTWM2OD1yLki3PFI4KM7:TR?= NXi3dVhsW0GQR1XS
ST486 MlPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPDTWM2OD1yLki3PVE4KM7:TR?= M2HNOXNCVkeHUh?=
KS-1 M3SzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rsc2lEPTB;MD64PFA6PiEQvF2= MX\TRW5ITVJ?
GDM-1 NX;oSGJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvkVpdKSzVyPUCuPFg3QDdizszN MW\TRW5ITVJ?
EHEB NGTPb|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwOUK1PFUh|ryP MnHuV2FPT0WU
LB2518-MEL MoXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLhTWM2OD1yLkmzNlg1KM7:TR?= NGTSdIhUSU6JRWK=
GOTO NXXySmVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr5VFhHUUN3ME2wMlk2ODd4IN88US=> MkjjV2FPT0WU
LXF-289 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHoUllKUUN3ME2wMlk2QTBzIN88US=> M{TvenNCVkeHUh?=
ES6 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fIdmlEPTB;MD65OlQ{PyEQvF2= MYfTRW5ITVJ?
OS-RC-2 M{fGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwOU[4N{DPxE1? NYrKWIFMW0GQR1XS
DMS-153 NX6ydpBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3odGNqUUN3ME2wMlk4PDZ7IN88US=> MkSwV2FPT0WU
SK-PN-DW M1PzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwOUe4N|Eh|ryP MlzPV2FPT0WU
HH MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwOUi5OVkh|ryP NGnHcZdUSU6JRWK=
SH-4 NULyNWlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTFwMEK0NUDPxE1? MXLTRW5ITVJ?
MOLT-4 MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnsTWM2OD1zLkCzOFU1KM7:TR?= MljYV2FPT0WU
TGW M2HIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwMEe2O|Uh|ryP NXPQeZY1W0GQR1XS
L-540 NHuxdHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrGe45KSzVyPUGuNVA3ODRizszN Ml:2V2FPT0WU
PF-382 M3rufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjrNGpKSzVyPUGuNVE2OTNizszN NWXlTnFtW0GQR1XS
LC-1F MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7JXJYxUUN3ME2xMlEzODB5IN88US=> M4\VWHNCVkeHUh?=
OVCAR-4 M{L6c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPrV5dKSzVyPUGuNVMyPjVizszN MXLTRW5ITVJ?
A4-Fuk M33yOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7nTWM2OD1zLkG1N|Y1KM7:TR?= M1Pmc3NCVkeHUh?=
HCC2218 NUnOe2VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXVTWM2OD1zLkG2OlQyKM7:TR?= NFv1O4RUSU6JRWK=
HAL-01 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfiNYNKSzVyPUGuNVY6PDNizszN NIK3RmNUSU6JRWK=
IST-MEL1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTFwMUe2OVkh|ryP NHTEfoJUSU6JRWK=
NCI-H719 NXzQVFdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[zSWxKSzVyPUGuNVc5QThizszN NF;m[4FUSU6JRWK=
EVSA-T MkOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHPfHJVUUN3ME2xMlE5OTF2IN88US=> Mnf3V2FPT0WU
SK-NEP-1 NVXkZWZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFwMkCyOlYh|ryP M1HuRXNCVkeHUh?=
OCUB-M M3rRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVW0PIRRUUN3ME2xMlIyPDh7IN88US=> NFXMUJhUSU6JRWK=
MEG-01 MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfjWHY2UUN3ME2xMlIzOTF6IN88US=> NFPycINUSU6JRWK=
no-10 M{jwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTFwMkOxNVIh|ryP MnXMV2FPT0WU
MHH-CALL-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjMTWM2OD1zLkK0O|IyKM7:TR?= MY\TRW5ITVJ?
SK-N-DZ NYO2UIIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7wNoNKSzVyPUGuNlQ4PzZizszN M3zzb3NCVkeHUh?=
SCLC-21H MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTFwMk[0O|gh|ryP MWfTRW5ITVJ?
CTV-1 M2LIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPnWnNKSzVyPUGuNlc1OjVizszN MUfTRW5ITVJ?
NB1 MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrZVGFKSzVyPUGuNlc4OzJizszN MlfPV2FPT0WU
NCI-H64 MoDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPuTWM2OD1zLkK4OFYzKM7:TR?= Ml\vV2FPT0WU
MDA-MB-134-VI NIXzdWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPsVolKSzVyPUGuNlg2PzdizszN MmjVV2FPT0WU
LB2241-RCC MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTFwMki2OlMh|ryP NYfuNWs1W0GQR1XS
8-MG-BA NF3TNlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTRZoxKSzVyPUGuNlg5PjZizszN MXLTRW5ITVJ?
LP-1 Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXyTWM2OD1zLkK5PVQ4KM7:TR?= MUfTRW5ITVJ?
LS-411N M3mxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXzcXdMUUN3ME2xMlMxQTl6IN88US=> NYX4TmFSW0GQR1XS
CAL-148 MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f6bmlEPTB;MT6zNlU1OiEQvF2= NVXOeWhuW0GQR1XS
NCI-H2171 MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTie5BKSzVyPUGuN|Q2ODJizszN M1X3U3NCVkeHUh?=
JiyoyeP-2003 NX\yZXhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HNSGlEPTB;MT6zOVM6KM7:TR?= MY\TRW5ITVJ?
NCI-H2107 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnKzTWM2OD1zLkO1PFg{KM7:TR?= NHn1SGxUSU6JRWK=
BB30-HNC M{HlUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHG0NnpKSzVyPUGuN|g6PzhizszN NWrxdmE6W0GQR1XS
K-562 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjt[FFXUUN3ME2xMlM6OjF7IN88US=> NFPWeo1USU6JRWK=
PSN1 M3PKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PFc2lEPTB;MT60NlI5PyEQvF2= Mm\EV2FPT0WU
HCC2157 MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;TPGxKSzVyPUGuOFI3QTFizszN MlK0V2FPT0WU
SBC-1 NFPxN4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPjTXBoUUN3ME2xMlQzPzRzIN88US=> M4\XVXNCVkeHUh?=
MC116 NYT3[3AzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPQTWM2OD1zLkSzOlE2KM7:TR?= M37J[XNCVkeHUh?=
KARPAS-422 M2XJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTFwNEWzOVgh|ryP Ml3OV2FPT0WU
LB996-RCC M{\We2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTFwNEexNFMh|ryP NXruVo5YW0GQR1XS
MSTO-211H NEPmTZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXCfXlKSzVyPUGuOFc6QDdizszN MVHTRW5ITVJ?
BT-474 NEXRSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jxPGlEPTB;MT61NVc3PCEQvF2= M2nacHNCVkeHUh?=
A388 M1jqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmj6TWM2OD1zLkWxPVQ2KM7:TR?= NFX3NWpUSU6JRWK=
SJSA-1 NV\aSFM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPQSG1KSzVyPUGuOVIzPiEQvF2= NEnwcpJUSU6JRWK=
COLO-829 M4jWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfXNWpKSzVyPUGuOVM2PjRizszN MX3TRW5ITVJ?
KM-H2 MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjzU3JKSzVyPUGuOVY3PyEQvF2= NIrNcY1USU6JRWK=
GR-ST NEDkN2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGG3O5RKSzVyPUGuOVY5OiEQvF2= NVfPNJdxW0GQR1XS
RPMI-8866 M{TwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXflR4RWUUN3ME2xMlYxOTR2IN88US=> MXXTRW5ITVJ?
KG-1 NGLDZoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HxTmlEPTB;MT62NVkxOSEQvF2= NXiwR2RtW0GQR1XS
NCI-H82 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFwNkO0NFYh|ryP M2rycXNCVkeHUh?=
LB1047-RCC M4Tifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTFwNkO0OVkh|ryP NIfFTVFUSU6JRWK=
KM12 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPDTWM2OD1zLk[0O{DPxE1? NXrKNGs4W0GQR1XS
NB5 NGDRNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIraZ3FKSzVyPUGuOlU3PzdizszN NVvBPWhIW0GQR1XS
HDLM-2 M1K3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnwU3ZKSzVyPUGuOlgzQDFizszN NH;VN2tUSU6JRWK=
KU812 NEWxbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\L[W9oUUN3ME2xMlY6PjB3IN88US=> MV\TRW5ITVJ?
DB M4LQNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGq1[GFKSzVyPUGuO|A{PTNizszN MXrTRW5ITVJ?
HD-MY-Z NWHCb|R5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkC1TWM2OD1zLke1NlM1KM7:TR?= NEG3c2xUSU6JRWK=
KURAMOCHI NGr4[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fqSWlEPTB;MT63O|IxPyEQvF2= NHzxcZdUSU6JRWK=
ETK-1 NUPRUnNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rUTGlEPTB;MT63PFg4QSEQvF2= M4e5bHNCVkeHUh?=
SK-UT-1 MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;MWY1KSzVyPUGuO|k{QDhizszN NVflOYRzW0GQR1XS
HUTU-80 MoD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVP2SVh[UUN3ME2xMlc6PTB6IN88US=> Mo\RV2FPT0WU
ES7 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHOO5FKUUN3ME2xMlgxOzB{IN88US=> NH21UYtUSU6JRWK=
SW872 NWD6V4xzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjUTWM2OD1zLkixN|k2KM7:TR?= NIDIV2lUSU6JRWK=
TK10 M3:3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DUbWlEPTB;MT64N|ExQCEQvF2= MknOV2FPT0WU
LB831-BLC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfGeVI6UUN3ME2xMlg{PTZ|IN88US=> NHjG[IFUSU6JRWK=
TE-9 M3Hnd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHIfJJHUUN3ME2xMlg1PDJ{IN88US=> M3jEOXNCVkeHUh?=
MLMA M13mXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPVfYg3UUN3ME2xMlg5OjN2IN88US=> NIrFfJhUSU6JRWK=
D-542MG MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnmR5Q3UUN3ME2xMlg6Ozd|IN88US=> NH3Xe5JUSU6JRWK=
EW-16 NFH6eI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;RWmlEPTB;MT65NlczKM7:TR?= MVzTRW5ITVJ?
LOXIMVI MoTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP3TWM2OD1zLkmzNlgh|ryP MlnoV2FPT0WU
GB-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILaPVRKSzVyPUGuPVM5PjZizszN MnLFV2FPT0WU
IST-SL2 M1;VNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJwMECyOlIh|ryP M1vLT3NCVkeHUh?=
LAN-6 M2j3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nIdWlEPTB;Mj6wNVk3PiEQvF2= MlXtV2FPT0WU
NCI-H510A NETPeppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJwMES1NFIh|ryP NFrrNIdUSU6JRWK=
NCI-H1092 M3HTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJwMEWxNlQh|ryP MVvTRW5ITVJ?
HT NU\hbpRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHjb|drUUN3ME2yMlExPDV2IN88US=> MYrTRW5ITVJ?
RL95-2 Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTJwMUG0PFIh|ryP M{PvSXNCVkeHUh?=
NCI-H1355 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HJXmlEPTB;Mj6xNVc6OiEQvF2= MmXsV2FPT0WU
NCI-H720 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjIfVRKSzVyPUKuNVY5PzNizszN MnXzV2FPT0WU
NCI-H1522 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVWzOVVbUUN3ME2yMlIyPzJ|IN88US=> MWnTRW5ITVJ?
LB373-MEL-D NWrRRYRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPoTWM2OD1{LkK2PVAzKM7:TR?= MUjTRW5ITVJ?
DG-75 NF7uWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mme4TWM2OD1{LkK3NVQ5KM7:TR?= NEfreGZUSU6JRWK=
ML-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2myVGlEPTB;Mj6zNlg2PSEQvF2= MW\TRW5ITVJ?
SF126 NIDUR2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mke3TWM2OD1{LkOzNFk1KM7:TR?= NXTw[ZNGW0GQR1XS
MPP-89 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mof2TWM2OD1{LkOzNVQ2KM7:TR?= NVnYS3dvW0GQR1XS
NCI-H345 NFjLcWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTJwM{OyO|ch|ryP NYDLeJB2W0GQR1XS
LS-123 M3HRPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV6zeWp6UUN3ME2yMlM1QTN4IN88US=> MUDTRW5ITVJ?
NB10 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGG3TZRKSzVyPUKuOFExQTJizszN Mm\uV2FPT0WU
CGTH-W-1 M2rzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXexXGNyUUN3ME2yMlQzOjZ5IN88US=> MmK1V2FPT0WU
CP66-MEL Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJwNEe3O{DPxE1? NHfQNpVUSU6JRWK=
L-428 NGXTXlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HBOmlEPTB;Mj60PFUzOSEQvF2= M2DNNXNCVkeHUh?=
DMS-79 NYLjN4h[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXNc3ZMUUN3ME2yMlU1OTB|IN88US=> NVzaTZZTW0GQR1XS
NCI-H1882 MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;M[49HUUN3ME2yMlY4PTZ{IN88US=> Mkj6V2FPT0WU
KGN MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnkWpMzUUN3ME2yMlc3QDd4IN88US=> NX\3V|ZXW0GQR1XS
EW-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnCTWM2OD1{Lke3NFg{KM7:TR?= MUXTRW5ITVJ?
U-266 NE\pUnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTJwOES4NlMh|ryP M3;XXHNCVkeHUh?=
COLO-320-HSR NVm3[Jd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTERo1wUUN3ME2yMlg2PjRzIN88US=> MYnTRW5ITVJ?
KMOE-2 NWTBdpozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NED5Wo5KSzVyPUKuPFc4OTFizszN MYnTRW5ITVJ?
BB49-HNC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rT[WlEPTB;Mj65NlQ5KM7:TR?= NFe3SY1USU6JRWK=
GI-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTRdGF4UUN3ME2yMlkzQTV5IN88US=> NInJ[VZUSU6JRWK=
NCI-H1304 NF\UN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTjfoVKSzVyPUOuNFA2OTFizszN NVHad3RIW0GQR1XS
NCI-H2227 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjueGl3UUN3ME2zMlAzODd7IN88US=> NICySmpUSU6JRWK=
U-87-MG M2Lo[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXlSmxKSzVyPUOuNFM2OTNizszN MknvV2FPT0WU
NCI-H747 NHi3fpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37vfmlEPTB;Mz6wOVIxPiEQvF2= NGfTNWZUSU6JRWK=
CTB-1 MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfkTHJKSzVyPUOuNFU{PzZizszN NWr6dZlYW0GQR1XS
RPMI-8226 NH[xcoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn75TWM2OD1|LkG0N|c5KM7:TR?= MX7TRW5ITVJ?
NCI-H2141 NVjrTogyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTNwMU[1OlYh|ryP M33MUnNCVkeHUh?=
IST-MES1 NGHqS5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrNTWM2OD1|LkG4Nlc6KM7:TR?= M4XoenNCVkeHUh?=
TE-5 NWfoWGxGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TzOWlEPTB;Mz6yNVM1OiEQvF2= MXjTRW5ITVJ?
UACC-257 NX7PN5JrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHvUIxKSzVyPUOuOFM3PTlizszN MU\TRW5ITVJ?
SK-N-FI M3\4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTNwNEWyNlch|ryP M3XQWXNCVkeHUh?=
MFH-ino MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fOPWlEPTB;Mz60OlU5QSEQvF2= M3PnfnNCVkeHUh?=
SF268 M2izSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnnd3VKSzVyPUOuOFgyPzRizszN NYrBeYUyW0GQR1XS
TE-12 MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfabVB2UUN3ME2zMlUyPjl7IN88US=> M1TGdnNCVkeHUh?=
NB6 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTNwNUW1OlMh|ryP NUXLZYJLW0GQR1XS
DJM-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTNwNUm4PVkh|ryP NEfqZpRUSU6JRWK=
MZ1-PC MmK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjlOIFKSzVyPUOuOlE3OjRizszN Mnq4V2FPT0WU
OCI-AML2 MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLC[W1tUUN3ME2zMlYzPjdzIN88US=> MkK1V2FPT0WU
NCI-H1155 Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HBeWlEPTB;Mz63NFk1PyEQvF2= M1Xi[nNCVkeHUh?=
RKO Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvWbpZKSzVyPUOuO|cyQDlizszN MV7TRW5ITVJ?
ECC4 NXP5VlFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPBTWM2OD1|Lkm3NVk2KM7:TR?= Mni1V2FPT0WU
BB65-RCC Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTNwOUe1OFch|ryP M{C1NXNCVkeHUh?=
EB-3 NHHPc|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1P6[WlEPTB;Mz65PVY{OyEQvF2= M{PIbnNCVkeHUh?=
SHP-77 NISzdXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HCcmlEPTB;ND6wNFUzPCEQvF2= MUPTRW5ITVJ?
NCI-H2196 M1:x[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjh[o5wUUN3ME20MlA2PjJ3IN88US=> MnnQV2FPT0WU
GI-ME-N MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\kXmlEPTB;ND6wOlM6QSEQvF2= NFPse4tUSU6JRWK=
MN-60 NEDISohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTRwMUC4O{DPxE1? M{DlNHNCVkeHUh?=
NCI-H1694 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPSblhMUUN3ME20MlE{PDB3IN88US=> MUHTRW5ITVJ?
LU-65 NFe0SJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTRwMUWzN|Ih|ryP NWTQN2UyW0GQR1XS
NCI-H1436 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[yVWlEPTB;ND6xPFM{OyEQvF2= NV;obVhGW0GQR1XS
KINGS-1 NXXre5Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHyNJh7UUN3ME20MlMyPDN{IN88US=> NXHLOYRWW0GQR1XS
GT3TKB MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu4OVhJUUN3ME20MlM{OjZ6IN88US=> M1y3N3NCVkeHUh?=
Becker MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTRwM{ezNVIh|ryP NHnLZWhUSU6JRWK=
HCC1187 MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rpbGlEPTB;ND64PVY2PyEQvF2= MV3TRW5ITVJ?
D-502MG M{\CWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DPRmlEPTB;NT6wNFQyPiEQvF2= NVrvd|hbW0GQR1XS
VA-ES-BJ MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3kRlRKSzVyPUWuNVM4PzhizszN NFrVdXZUSU6JRWK=
NB7 M{fYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTwTWM2OD13LkG0NVEzKM7:TR?= NHe3bZRUSU6JRWK=
SW962 M1;hW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofITWM2OD13LkO4PFE1KM7:TR?= MkjQV2FPT0WU
no-11 M2PvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTVwN{[zOFMh|ryP M2LiPHNCVkeHUh?=
KNS-81-FD M1rwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17BbGlEPTB;NT65NFY6PCEQvF2= Mlr4V2FPT0WU
COLO-684 NVzNcVF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDXOmsxUUN3ME21Mlk6PDl2IN88US=> MlTxV2FPT0WU
D-263MG M2\pOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\HTWM2OD14LkC4PFk2KM7:TR?= MnKxV2FPT0WU
EW-24 MmWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPjbJVIUUN3ME22MlI5PTFizszN MVXTRW5ITVJ?
TE-10 M2LRU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTZwNEK2NlMh|ryP MmPYV2FPT0WU
EKVX M4i3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTZwNE[zNlEh|ryP NV;xdpJPW0GQR1XS
NCI-H1648 NF;NXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFn1Um9KSzVyPU[uOlc2PTdizszN NXH1PJRpW0GQR1XS
LB771-HNC Mn7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvKboN[UUN3ME22MlkzOzBzIN88US=> MlT6V2FPT0WU
SK-MEL-1 MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX4eZlGUUN3ME24MlE{OTZ4IN88US=> MoO0V2FPT0WU
COLO-668 MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFO4OnhKSzVyPUiuNlc4QDZizszN NX:xNI4zW0GQR1XS
EW-12 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHaZpRKSzVyPUiuOFA5ODNizszN NIjVd3lUSU6JRWK=
A253 MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnKNXpKSzVyPUiuPFQ3PjFizszN NIDtPJlUSU6JRWK=
NCI-H2126 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3r1U2lEPTB;OD64PVMyQSEQvF2= Ml63V2FPT0WU
Calu-6 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTafFhpUUN3ME24Mlk6ODR{IN88US=> NVnhZWpuW0GQR1XS
NCI-H23 M2jHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3n0RmlEPTB;OT6xO|c1PiEQvF2= MXXTRW5ITVJ?
WSU-NHL MnX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\3TWM2OD17Lke3OFc5KM7:TR?= NHHCNm5USU6JRWK=
MMAC-SF MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\ETmlEPTB;OT65O|kxPCEQvF2= MlXZV2FPT0WU
SK-LMS-1 NVe0VWpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Tk[WlEPTB;MUCuNlg{PCEQvF2= NWn3RVg1W0GQR1XS
GCIY NHj2WGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULyb483UUN3ME2xNE42QTJ2IN88US=> NH;aPGZUSU6JRWK=
TE-15 NYi5T|h3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTFzLk[wNFQh|ryP MlnJV2FPT0WU
EoL-1-cell NWjoRXpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LpSWlEPTB;MUGuO|Y5OiEQvF2= NHHjOlRUSU6JRWK=
NCI-H2081 M1uwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTFzLke3PFYh|ryP MUnTRW5ITVJ?
EW-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PBVmlEPTB;MUKuNlQ3OyEQvF2= NWSzcYF1W0GQR1XS
CAS-1 M1rYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTF{LkO2N|Eh|ryP MUXTRW5ITVJ?
C2BBe1 MnO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DqdmlEPTB;MUKuOlE{OSEQvF2= NGD5ToVUSU6JRWK=
D-247MG MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TZWmlEPTB;MUKuO|k2OiEQvF2= MlK2V2FPT0WU
NCI-SNU-5 M33uZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjDNYJKSzVyPUGyMlgxOTNizszN NFfOb5hUSU6JRWK=
LS-1034 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Pkd2lEPTB;MUSuN|k4PSEQvF2= MYDTRW5ITVJ?
EW-18 NHvxNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3HNXFKSzVyPUG0MlQ1QCEQvF2= MX7TRW5ITVJ?
Raji NGX1WpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jTTGlEPTB;MUSuOVA1QSEQvF2= NFzEWnVUSU6JRWK=
D-283MED NIjTO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X0fGlEPTB;MUSuOlI4OSEQvF2= Mn;HV2FPT0WU
MZ2-MEL NY\YWIdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Xmc2lEPTB;MUSuPVY6PiEQvF2= M{TzPHNCVkeHUh?=
NCI-SNU-16 NYfJWYE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1yxRWlEPTB;MUWuOFY{OyEQvF2= MVzTRW5ITVJ?
P30-OHK M4PzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DMVGlEPTB;MUeuO|g{OSEQvF2= MXTTRW5ITVJ?
RXF393 NIjoZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjl[XhKSzVyPUG5MlAyQDZizszN M1zBXnNCVkeHUh?=
NCI-H1395 NHGxToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPOeXNyUUN3ME2yNE43PzB|IN88US=> NH\oU4hUSU6JRWK=
U-698-M NVLiR|dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PRPGlEPTB;MkCuO|A4PSEQvF2= M1\IO3NCVkeHUh?=
NCI-SNU-1 MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTJyLkeyNlMh|ryP MXXTRW5ITVJ?
SW684 Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJzLkG3NVYh|ryP NVfOe|BkW0GQR1XS
NCI-H716 NIrSN|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\4VYZRUUN3ME2yNU4{OTV2IN88US=> MnjQV2FPT0WU
JVM-2 M3rjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rjdWlEPTB;MkGuOFE{OyEQvF2= MWDTRW5ITVJ?
NCI-H1581 MmTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTpTYZbUUN3ME2yNk41OTR6IN88US=> NEnIO21USU6JRWK=
CA46 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jZTWlEPTB;M{GuOlk{PiEQvF2= M1vyW3NCVkeHUh?=
SNB75 NV7VcHR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\xTWM2OD1|Mz62OVA{KM7:TR?= MX7TRW5ITVJ?
KNS-42 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jFZWlEPTB;M{WuPVYzPCEQvF2= MmLMV2FPT0WU
TUR MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDXTWM2OD1|Nj6wOVIyKM7:TR?= NHy2UpRUSU6JRWK=
REH MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTN5LkiyNVEh|ryP MkHIV2FPT0WU
EW-22 MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlG3TWM2OD12Mj6yPFg2KM7:TR?= NG\lVY1USU6JRWK=
NCI-H446 M4WwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\zTFNUUUN3ME20Nk44QDV|IN88US=> MUjTRW5ITVJ?
ES3 MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrLTWM2OD12Mz6xN|M6KM7:TR?= Mnn5V2FPT0WU
EW-11 NFzXRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjKV3lpUUN3ME20OE45OjF6IN88US=> NYDjZYJDW0GQR1XS
RH-1 M1raV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrUSINPUUN3ME20O{42QDF{IN88US=> NWrFc4ZmW0GQR1XS

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[6]

+ 展開

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
細胞試験:

[2]

+ 展開
  • 細胞株: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • 濃度: ~ 10 μM
  • 反応時間: 3 days
  • 実験の流れ:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • 製剤: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • 投薬量: 12.3, 24.5 and 49 mg/kg
  • 投与方法: Administered orally once daily 5 days per week for 4 weeks
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+ddH2O
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 376.41
化学式

C21H20N4O3

CAS No. 209783-80-2
保管
in solvent
別名 SNDX-275

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03473639 Recruiting Metastatic Breast Cancer|Breast Cancer University of Virginia|Syndax Pharmaceuticals December 15 2018 Phase 1
NCT03552380 Recruiting Renal Cell Carcinoma Roberto Pili|Bristol-Myers Squibb|Syndax Pharmaceuticals|Indiana University School of Medicine|Hoosier Cancer Research Network August 31 2018 Phase 2
NCT03538171 Recruiting Advanced Breast Cancer EddingPharm Oncology Co. LTD. May 15 2018 Phase 3
NCT03501381 Recruiting Renal Cell Carcinoma Roberto Pili|Indiana University Melvin and Bren Simon Cancer Center|Prometheus Laboratories|Syndax Pharmaceuticals|Hoosier Cancer Research Network May 24 2018 Phase 2
NCT02697630 Recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals February 21 2018 Phase 2
NCT03361800 Recruiting Breast Cancer|Invasive Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals|National Cancer Institute (NCI) January 22 2018 Early Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • 回答:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Entinostat (MS-275)を買う | Entinostat (MS-275) ic50 | Entinostat (MS-275)供給者 | Entinostat (MS-275)を購入する | Entinostat (MS-275)費用 | Entinostat (MS-275)生産者 | オーダーEntinostat (MS-275) | Entinostat (MS-275)化学構造 | Entinostat (MS-275)分子量 | Entinostat (MS-275)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID